{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:26:19Z","timestamp":1793042779017,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejim.2023.10.013","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:36:27Z","timestamp":1697312187000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Residual cardiovascular risk: When should we treat it?"],"prefix":"10.1016","volume":"120","author":[{"given":"Francisco","family":"Gomez-Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Raya-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Delgado-Lista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Perez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2023.10.013_bib0001","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European society of cardiology: cardiovascular disease statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.013_bib0002","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.013_bib0004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.rce.2014.06.001","article-title":"Atherogenic dyslipidemia: prevalence and management in lipid clinics","volume":"214","author":"Pedro-Botet","year":"2014","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.ejim.2023.10.013_bib0005","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/jcm12041382","article-title":"Current and emerging therapies for atherosclerotic cardiovascular disease risk reduction in hypertriglyceridemia","volume":"12","author":"Mszar","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0006","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0007","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020377","article-title":"Triglyceride levels and residual risk of atherosclerotic cardiovascular disease events and death in adults receiving statin therapy for primary or secondary prevention: insights from the KP REACH study","volume":"10","author":"Ambrosy","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2023.10.013_bib0009","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jacl.2022.09.005","article-title":"Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the multi-ethnic study of atherosclerosis (MESA)","volume":"16","author":"Chevli","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0010","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1161\/ATVBAHA.123.319297","article-title":"Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes: a mendelian randomization study","volume":"43","author":"Navarese","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0011","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamacardio.2021.5080","article-title":"Apolipoprotein B vs. low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein-related risk: the debate is over","volume":"7","author":"Sniderman","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0012","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0013","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","article-title":"Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial","volume":"399","author":"Delgado-Lista","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejim.2023.10.013_bib0014","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"Suppl 2","key":"10.1016\/j.ejim.2023.10.013_bib0016","first-page":"69","article-title":"Treatment of mild-to-moderate hypertriglyceridemia","volume":"33","author":"P\u00e9rez-Mart\u00ednez","year":"2021","journal-title":"Clin Investig Arterioscler Publ Soc Esp Arterioscler"},{"key":"10.1016\/j.ejim.2023.10.013_bib0017","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0019","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejim.2023.10.013_bib0021","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2023.10.013_bib0022","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0023","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0024","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.013_bib0025","unstructured":"A study of olezarsen (ISIS 678354) administered to participants with severe hypertriglyceridemia - full text view - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05079919 (accessed June 25, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0026","unstructured":"A study of olezarsen (formerly known as AKCEA-APOCIII-LRx) administered to patients with familial chylomicronemia syndrome (FCS) - full text view - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04568434 (accessed June 25, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0027","doi-asserted-by":"crossref","first-page":"82","DOI":"10.17925\/EE.2022.18.2.82","article-title":"APOC3 interference for familial chylomicronaemia syndrome","volume":"18","author":"Hegele","year":"2022","journal-title":"TouchRev Endocrinol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0028","unstructured":"Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia | Circulation n.d. https:\/\/www.ahajournals.org\/doi\/10.1161\/circ.144.suppl_1.10357 (accessed June 25, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0029","unstructured":"Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia - Full Text View - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04720534 (accessed June 25, 2023)."},{"issue":"23","key":"10.1016\/j.ejim.2023.10.013_bib0030","first-page":"S1050","article-title":"ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases","author":"Luo","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0031","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0032","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0033","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40265-021-01516-y","article-title":"Evinacumab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2023.10.013_bib0034","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.013_bib0035","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.10.013_bib0036","unstructured":"Inc I.P. Pfizer and Ionis announce discontinuation of vupanorsen clinical development program n.d. https:\/\/www.prnewswire.com\/news-releases\/pfizer-and-ionis-announce-discontinuation-of-vupanorsen-clinical-development-program-301471041.html (accessed July 17, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0037","unstructured":"RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia | European Heart Journal | Oxford Academic n.d. https:\/\/academic-oup-com.bvsspa.idm.oclc.org\/eurheartj\/article\/41\/Supplement_2\/ehaa946.3331\/6004712 (accessed June 25, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0038","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ejim.2023.10.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule","volume":"2020","author":"Jawi","year":"2020","journal-title":"J Lipids"},{"key":"10.1016\/j.ejim.2023.10.013_bib0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MCA.0000000000001233","article-title":"Lipoprotein(a) is associated with premature coronary artery disease: a meta-analysis","volume":"34","author":"Papathanasiou","year":"2023","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.ejim.2023.10.013_bib0041","doi-asserted-by":"crossref","first-page":"15660","DOI":"10.1038\/s41598-021-95141-0","article-title":"Lipoprotein (a) level as a risk factor for stroke and its subtype: a systematic review and meta-analysis","volume":"11","author":"Kumar","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2023.10.013_bib0042","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1358863X221091320","article-title":"Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: a systematic review","volume":"27","author":"Masson","year":"2022","journal-title":"Vasc Med Lond Engl"},{"key":"10.1016\/j.ejim.2023.10.013_bib0043","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(a) and calcific aortic valve stenosis: a systematic review","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2023.10.013_bib0044","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10654-022-00956-4","article-title":"Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis","volume":"38","author":"Amiri","year":"2023","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0045","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2174\/0929867324666170112111948","article-title":"Lipoprotein (a) and cardiovascular risk: the show must go on","volume":"24","author":"Katsiki","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ejim.2023.10.013_bib0046","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0047","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0048","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.013_bib0049","doi-asserted-by":"crossref","first-page":"12581","DOI":"10.1002\/jcp.28134","article-title":"Dietary natural products as emerging lipoprotein(a)-lowering agents","volume":"234","author":"Momtazi-Borojeni","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0050","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.013_bib0051","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0052","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0053","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FJC.0000000000000963","article-title":"Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0054","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0055","first-page":"577","article-title":"Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a)","volume":"16","author":"Katsiki","year":"2023","journal-title":"Pharm (Basel Switz)"},{"key":"10.1016\/j.ejim.2023.10.013_bib0056","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","article-title":"Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease","volume":"13","author":"Moriarty","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0057","unstructured":"Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes - Full Text View - ClinicalTrials.gov n.d. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02791802 (accessed June 22, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0058","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA therapeutics to lower blood levels of Lp(a): JACC focus seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0059","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejim.2023.10.013_bib0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0061","unstructured":"Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD - Full Text View - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04023552 (accessed June 22, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0062","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0063","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0064","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0065","unstructured":"Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial - Full Text View - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05581303 (accessed June 22, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0066","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2023.10.013_bib0067","unstructured":"Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) - Full Text View - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04606602 (accessed June 22, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2023.10.013_bib0069","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2023.10.013_bib0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ehjqcco\/qcz055","article-title":"Residual inflammatory risk after contemporary lipid lowering therapy","volume":"6","author":"Riaz","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.ejim.2023.10.013_bib0071","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejim.2023.10.013_bib0072","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejvs.2017.05.009","article-title":"Systematic review and meta-analysis of the association between C-reactive protein and major cardiovascular events in patients with peripheral artery disease","volume":"54","author":"Singh","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejim.2023.10.013_bib0073","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.10.013_bib0074","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3390\/ijms24032079","article-title":"Monomeric C-reactive protein in atherosclerotic cardiovascular disease: advances and perspectives","volume":"24","author":"Melnikov","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2023.10.013_bib0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13679-022-00481-1","article-title":"Mediterranean diet and obesity-related disorders: what is the evidence?","volume":"11","author":"Muscogiuri","year":"2022","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.ejim.2023.10.013_bib0076","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/10408398.2020.1764487","article-title":"Dietary habits, lipoprotein metabolism and cardiovascular disease: from individual foods to dietary patterns","volume":"61","author":"Gomez-Delgado","year":"2021","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.ejim.2023.10.013_bib0077","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1097\/HJH.0000000000002581","article-title":"Effect of aerobic and resistance exercise training on inflammation, endothelial function and ambulatory blood pressure in middle-aged hypertensive patients","volume":"38","author":"Boeno","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.10.013_bib0078","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12872-019-1184-2","article-title":"Effects of ezetimibe\/simvastatin 10\/10\u00a0mg versus rosuvastatin 10\u00a0mg on carotid atherosclerotic plaque inflammation","volume":"19","author":"Oh","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2023.10.013_bib0079","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.10.013_bib0080","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2995602","article-title":"Ezetimibe improves rosuvastatin effects on inflammation and vascular endothelial function in acute coronary syndrome patients undergoing PCI","volume":"2021","author":"Sun","year":"2021","journal-title":"J Intervent Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0081","doi-asserted-by":"crossref","first-page":"8087","DOI":"10.1111\/jcmm.16798","article-title":"Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy","volume":"25","author":"Li","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0082","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0083","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","article-title":"Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial","volume":"13","author":"Shah","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2023.10.013_bib0084","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2022.06.028","article-title":"Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: a combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies","volume":"363","author":"Sun","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2023.10.013_bib0085","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/MJT.0000000000001409","article-title":"Effect of colchicine in reducing inflammatory biomarkers and cardiovascular risk in coronary artery disease: a meta-analysis of clinical trials","volume":"30","author":"Sethuramalingam","year":"2023","journal-title":"Am J Ther"},{"key":"10.1016\/j.ejim.2023.10.013_bib0086","unstructured":"FDA Approves Colchicine for Decreasing CV Events. TCTMDCom 2023. https:\/\/www.tctmd.com\/news\/fda-approves-colchicine-decreasing-cv-events (accessed June 24, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0087","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0088","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejim.2023.10.013_bib0089","first-page":"117","article-title":"Effect of bempedoic acid on atherogenic lipids and inflammation: a meta-analysis","volume":"33","author":"Masson","year":"2021","journal-title":"Clin Investig Arterioscler Publ Soc Esp Arterioscler"},{"key":"10.1016\/j.ejim.2023.10.013_bib0090","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ejim.2023.10.013_bib0091","unstructured":"ZEUS A. Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation - Full Text View - ClinicalTrials.gov n.d. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05021835 (accessed June 24, 2023)."},{"key":"10.1016\/j.ejim.2023.10.013_bib0092","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","year":"2018","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ejim.2023.10.013_bib0093","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMra2030281","article-title":"Pollution and the Heart","volume":"385","author":"Rajagopalan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.013_bib0094","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cca.2018.05.046","article-title":"Uric acid and cardiovascular disease","volume":"484","author":"Ndrepepa","year":"2018","journal-title":"Clin Chim Acta"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2023.10.013_bib0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13646","article-title":"Residual cardiovascular risk among people with diabetes","volume":"21","author":"Dash","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2023.10.013_bib0096","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.endinu.2019.05.004","article-title":"Evaluation and management of residual cardiovascular risk in patients with diabetes","volume":"67","author":"Gimeno Orna","year":"2020","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.ejim.2023.10.013_bib0097","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz404","article-title":"Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial","volume":"40","author":"de Vries","year":"2019","journal-title":"Eur Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T22:38:55Z","timestamp":1715899135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523003680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":97,"alternative-id":["S0953620523003680"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.10.013","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual cardiovascular risk: When should we treat it?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}